Jubilant Pharmova share price has plunged 5% and is presently trading at Rs 1,207.7.
Meanwhile, the BSE HEALTHCARE index is at 43,679.2 (down 1.2%).
Among the top losers in the BSE HEALTHCARE index today are Sun Pharma (down 3.9%) and CAPLIN POINT (down 3.7%).
KIMS (up 2.9%) and MAX HEALTHCARE INSTITUTE (up 1.4%) are among the top gainers today.
Over the last one year, Jubilant Pharmova has moved up from Rs 374.5 to Rs 1,207.7, registering a gain of Rs 833.2 (up 222.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,271.8 to 43,679.2, registering a gain of 60.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 222.5%), SUVEN PHARMACEUTICALS (up 128.4%) and Glenmark Pharma (up 122.9%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 78,569.4 (down 1.6%).
The top losers among the BSE Sensex today are Sun Pharma (down 3.9%) and NTPC (down 3.8%). The most traded stocks in the BSE Sensex are ICICI Bank and Reliance Ind..
In the meantime, NSE Nifty is at 23,919.1 (down 1.6%). IOC and Hero Motocorp are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 63,874.9 to 78,569.4, registering a gain of 14,694.5 points (up 23.0%).
Jubilant Pharmova net profit grew 93.2% YoY to Rs 1,026 million for the quarter ended September 2024, compared to a profit of Rs 531 million a year ago. Net sales rose 4.3% to Rs 17,523 million during the period as against Rs 16,803 million in July-September 2023.
For the year ended March 2024, Jubilant Pharmova reported 212.0% increase in net profit to Rs 727 million compared to net loss of Rs 649 million during FY23. Revenue of the company grew 6.7% to Rs 67,029 million during FY24.
The current Price to earnings ratio of Jubilant Pharmova, based on rolling 12 month earnings, stands at 33.6.
Equitymaster requests your view! Post a comment on "Jubilant Pharmova Plunges 5%; BSE HEALTHCARE Index Down 1.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!